en
Scientific article
English

A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study

Published inThe American journal of gastroenterology, vol. 102, no. 7, p. 1397-1405
Publication date2007
Abstract

In patients with cirrhosis, acute octreotide administration may transiently decrease the hepatic venous pressure gradient (HVPG). Information on long-term effects of octreotide is limited and controversial. We evaluated portal and systemic hemodynamics following a prolonged administration of long-acting octreotide in patients with cirrhosis.

Keywords
  • Adult
  • Aged
  • Biological Markers/blood
  • Biopsy
  • Delayed-Action Preparations
  • Double-Blind Method
  • Endothelin-1/blood
  • Female
  • Follow-Up Studies
  • Gastrointestinal Agents/administration & dosage/pharmacokinetics
  • Humans
  • Hypertension, Portal/drug therapy/etiology/physiopathology
  • Immunoenzyme Techniques
  • Injections, Intramuscular
  • Liver Cirrhosis/blood/complications/pathology
  • Male
  • Middle Aged
  • Octreotide/administration & dosage/pharmacokinetics
  • Portal Pressure/physiology
  • Radioimmunoassay
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome
  • Urotensins/blood
  • Vascular Endothelial Growth Factor A/blood
Citation (ISO format)
SPAHR, Laurent François Joséph et al. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. In: The American journal of gastroenterology, 2007, vol. 102, n° 7, p. 1397–1405. doi: 10.1111/j.1572-0241.2007.01262.x
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0002-9270
564views
0downloads

Technical informations

Creation03/28/2014 11:30:00 AM
First validation03/28/2014 11:30:00 AM
Update time03/14/2023 9:04:19 PM
Status update03/14/2023 9:04:19 PM
Last indexation01/16/2024 9:32:27 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack